Published online by Cambridge University Press: 06 January 2021
1 Erdman, Joanna N., Human Rights in Health Equity: Cervical Cancer and HPV Vaccines, 35 Am. J. L. & Med. 365, 366 (2009).Google Scholar
2 See Gakidou, Emmanuela et al., Coverage of Cervical Cancer Screening in 57 Countries: Low Average Levels and Large Inequalities, 5 Plos Medicine 863, 863 (2008);Google Scholar Sankaranarayanan, R. et al., Effective Screening Programmes for Cervical Cancer in Low- and Middle-Income Developing Countries, 79 Bulletin of the World Health Organization 954-62 (2001).Google ScholarPubMed
7 Outterson & Kesselheim, supra note 5, at 134-35.
11 Effort, April E. & Stevens, Ashley J., Using Academic License Agreements to Promote Global Social Responsibility, 43 Les Nouvelles: J. Licensing Executives Soc’y 85 (2008)Google Scholar. Ashley Stevens discussed this paper at the Symposium.
13 Mexico is not a Revolving Fund recipient country.
14 The cost effective price in Brazil has been estimated at approximately $25. Agosti, Jan M. & Goldie, Sue J., Introducing HPV Vaccine in Developing Countries – Key Challenges and Issues, 356 New Eng. J. Med. 1908, 1909-10 (2007)CrossRefGoogle ScholarPubMed. In poorer countries with per capital incomes around $1000, the cost effective price is in the range of $3 to $6. Helen Saxenian, Program for Appropriate Technology Health (PATH), HPV Vaccine Adoption in Developing Countries: Cost and Financing Issues 8-11 (2007).
18 U.N. Convention on the Rights of the Child, G.A. Res. 44/25, U.N. Doc. A/RES/44/25 (Nov. 20, 1989), at Art. 24. The United States is not a party to this Convention.
19 English, supra note 17.
20 Erdman, supra note 1.
21 Erdman, supra note 1, at 380.
22 Id. at 381.
25 Id. at 404-05.
26 Id. at 408.
27 Outterson & Kesselheim, supra note 5, at 135.
Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.